Breaking the CLD Bottleneck: Generate Stable High-Producing Clones in 14 Weeks

Given its inherent time and resource demands, variability in productivity, and the rising complexity of monoclonal antibody (mAb) modalities—including bispecific antibodies (bsAb) and fusion proteins—cell line development (CLD) has become a leading constraint on bioprocess development.

Designed to address these constraints, the Gibo™ CHOvantage™ GS CLD kit is a transposon-based CHO-K1 CLD platform that offers a solution for the accelerated production of stable, high-performing cell lines. Using this platform, mAb, bsAb, and Fc-fusion protein cell lines were generated in less than 14 weeks with high-titer pools consistently producing up to 5 g/L and corresponding stable clone titers reaching greater than 7 g/L. Selected clones were successfully scaled to bench scale and found to be stable in production and product quality for up to 100 generations. Collectively, this demonstrates that the CHOvantage™ platform enables rapid, robust, and scalable generation of high-producing cell lines and represents an effective solution for accelerating biotherapeutic development.